The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Cytokine Release Syndrome Treatment Market During The Forecast Period 2026–2030?
The cytokine release syndrome treatment market size has recently seen rapid growth. It is expected to expand from $1.42 billion in 2025 to $1.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.6%. The historical expansion of this market can be attributed to an increase in advanced immunotherapy treatments, broader adoption of CAR-T cell therapy, the availability of corticosteroids for immune modulation, heightened clinical awareness of cytokine storms, and advancements in critical care infrastructure.
The cytokine release syndrome treatment market is anticipated to experience substantial growth in the coming years. It is projected to reach $2.66 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.3%. This expansion during the forecast period can be attributed to several factors, including the increasing application of next-generation immunotherapies, rising investments in cytokine modulation research, the expansion of oncology treatment centers, a growing focus on personalized immune management, and the development of novel anti-inflammatory biologics. Significant trends expected in this period encompass the increasing use of IL-6 and IL-1 targeted therapies, the rising adoption of monoclonal antibodies for CRS management, the broadening of hospital-based CRS treatment protocols, an expanding integration of early diagnostic monitoring, and improved supportive care management strategies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20542&type=smp
Which Economic Or Industry Drivers Are Impacting The Cytokine Release Syndrome Treatment Market?
The future expansion of the cytokine release syndrome (CRS) treatment market is projected to be driven by the increasing volume of cancer treatments. The rise in cancer treatments is influenced by the global increase in cancer cases and advancements in diagnostic technologies, enabling earlier detection and a wider array of treatment possibilities. Moreover, improved survival outcomes and broader access to healthcare facilities contribute to the rising need for these therapies. CRS treatment includes supportive measures, anti-cytokine medications, and continuous monitoring to manage symptoms and mitigate the inflammatory response induced by cancer treatments. For example, in May 2024, the National Health Service (NHS), a UK-based healthcare system, reported that nearly 340,000 individuals commenced their initial cancer treatment in the period from April 2023 to March 2024. Furthermore, urgent suspected cancer referrals reached a new peak in March 2024, with 12,554 patients seen per working day, exceeding the prior record of 12,376 patients seen per working day in July 2023. Consequently, the increasing prevalence of cancer treatments is fueling the cytokine release syndrome treatment market.
What Market Segments Are Evaluated Within The Cytokine Release Syndrome Treatment Market?
The cytokine release syndrome treatment market covered in this report is segmented –
1) By Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants
2) By Administration: Intravenous, Subcutaneous, Oral
3) By Application: Oncological Treatments, Autoimmune Disorders, Other Applications
4) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor), Siltuximab (IL-6 Inhibitor), Anakinra (IL-1 Receptor Antagonist)
3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor (TNF) Inhibitors
What Industry Trends Are Redefining The Cytokine Release Syndrome Treatment Market?
Major companies operating within the cytokine release syndrome treatment market are advancing drug delivery technologies, including intravenous infusion, to enhance treatment precision, reduce side effects, and improve patient outcomes. Intravenous infusion, when utilized in the treatment of cytokine release syndrome, enables the swift and accurate delivery of drugs into the bloodstream, ensuring rapid therapeutic action. For instance, in September 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received regulatory approval for Actemra (tocilizumab), a humanized anti-IL-6 receptor monoclonal antibody, from the Ministry of Health, Labor, and Welfare, a Japan-based government authority, to treat cytokine release syndrome (CRS) induced by various cancer therapies. Actemra Intravenous Infusion (available in 80 mg, 200 mg, and 400 mg doses) is an additional indication for treating cytokine release syndrome (CRS) caused by cancer therapy. With this new indication, Actemra can now be used as an anti-cytokine therapy for CRS resulting from cancer treatments beyond tumor-specific T-cell infusion therapy.
Who Are The Top Market Participants Influencing The Cytokine Release Syndrome Treatment Market?
Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.
Read the full cytokine release syndrome treatment market report here:
What Are The Top-Performing Regions Within The Cytokine Release Syndrome Treatment Market?
North America was the largest region in the cytokine release syndrome treatment market in 2025. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Cytokine Release Syndrome Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20542&type=smp
Browse Through More Reports Similar to the Global Cytokine Release Syndrome Treatment Market 2026, By The Business Research Company
Drugs For Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report
Cellulars Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Cancer Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model